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Background: The effect of reactive oxygen species (ROS) on platelet function in coronary heart disease (CHD)
is complex and poorly deﬁned. Platelet aggregation studies in healthy volunteers have demonstrated con-
trasting results when platelets are exposed to ROS. We investigated the effect of ROS on whole blood aggre-
gation (WBA) and the endothelial cell-platelet interaction in patients with CHD.
Methods and Results: ROS generated by xanthine and xanthine oxidase caused a concentration-dependent in-
hibition of WBA in blood from healthy donors and patients with CHD. In patients with CHD, 100 μM xanthine
and 100 mU/ml xanthine oxidase inhibited WBA in response to 3 μg/ml collagen by 28.9% (95% CI 15.9%-
41.8%, pb0.001) and in response to 5 μM ADP by 36.0% (95% CI 9.6%-62.4%, p=0.005). Using nitrotyrosine
expression, platelets isolated from patients with CHD were found to be susceptible to peroxynitrite damage.
The addition of 1×105 cultured endothelial cells inhibited WBA in response to 3 μg/ml collagen by 31.2%
(95% CI 12.2%-50.2%, pb0.05) and in response to 5 μM ADP by 31.6% (95% CI 2.5-60.7%, pb0.05). Addition
of xanthine and xanthine oxidase did not alter this effect, however pre-treatment of endothelial cells with
a nitric oxide synthase inhibitor (L-NAME) partly reversed the inhibition.
Conclusion: ROS inhibit WBA in blood from patients with CHD. Whilst endothelial cells also inhibit WBA, the
effect is attenuated by L-NAME, suggesting that nitric oxide is likely to remain an important protective mech-
anism against thrombosis in CHD.© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Oxidative stress is recognised as an important mediator of athero-
thrombotic events in cardiovascular disease [1]. The classic paradigm
of atherothrombosis involves the formation of platelet-rich thrombus
overlying damaged endothelium,whichmay result fromoxidative inju-
ry. In addition to other factors, reactive oxygen species (ROS) directly
participate in the regulation of platelet activation and thrombus forma-
tion, however the direct effects of ROS on platelets are reportedly var-
ied. Previous platelet studies in healthy individuals have reported
both pro- and anti-aggregatory effects when platelets are exposed to
exogenous ROS [2]. Platelets themselves also generate ROS through sev-
eral intracellular sources such as NADPH oxidase, cyclooxygenase,
uncoupled endothelial nitric oxide synthase (eNOS), xanthine oxidase.
NC-ND license.(XO) and mitochondrial respiration (reviewed extensively in [2]) and
this appears to be important during recruitment, adhesion and aggrega-
tion as well as during activation to agents such as collagen [3].
As healthy endothelium normally inhibits thrombosis, the in-
teractions between ROS, endothelial cells (ECs) and platelets are
integral to the pathogenesis of cardiovascular events. Although
there is good evidence that oxidative stress damages the endothe-
lium in vivo, which predisposes individuals to thrombosis, the close
interactions between ROS and ECs are not well understood. WBA
offers the most physiological setting in which to examine platelet
aggregation as it closely replicates the milieu in which clinical
thrombosis occurs, where other blood constituents, including
erythrocytes [4], leucocytes [5] and plasma-derived substances
[6,7] are involved. ECs normally inhibit platelet aggregation by re-
lease of nitric oxide (•NO) [8], prostacyclin [9], and the activity of
endothelial ectonucleotidases [10], although in the presence of
heightened oxidative stress, some of these effects may be deﬁcient.
Our aims were to quantify the effects of ROS on WBA and to assess
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coronary heart disease (CHD).Material and methods
Study population
This study was approved by the West Glasgow and University of
Strathclyde ethics committees. All participants were provided with a
Participant Information Sheet and gave their informed written con-
sent. All CHD patients recruited to the study attended theWestern In-
ﬁrmary Glasgow for out-patient cardiology appointments, were over
18 years old and were receiving chronic oral aspirin therapy. Patients
were excluded if there was a history of myocardial infarction within
3 months, if they were unable to give informed consent or if they
were taking any other antithrombotic therapy. For comparison,
blood samples were collected from healthy donors with no history
of CHD.Chemiluminescence
Lucigenin chemiluminescence was used to conﬁrm generation
of ROS (speciﬁcally superoxide anion [O2-•]) as a consequence of
the xanthine/xanthine oxidase (X/XO) reaction [11]. Brieﬂy,
900 μl of PBS and 100 μl lucigenin solution (Sigma-Aldrich, Dorset,
UK) were prewarmed in a sample cuvette at 37 °C, then xanthine
and XO (Sigma-Aldrich, Dorset, UK) were added before transfer-
ring immediately to a chemiluminometer (Berthold, Germany).
The chemiluminescence signal was recorded after 120 seconds.
Xanthine and XO were dissolved in 10 mM NaOH and PBS respec-
tively, and tested at a range of concentrations likely to generate
ROS. As lucigenin itself can interfere with O2-• generation, thus
affecting chemiluminescence [12], 5 μM lucigenin was used to
minimise this interference.Whole blood aggregometry
Venous blood was withdrawn into 3.5 ml Vacuette® tubes con-
taining 3.2% sodium citrate (1:9 volume). Blood was tested up to
3 hours following venepuncture. WBAwas measured using an imped-
ance aggregometer (Chrono-log, Model 590). 500 μl citrated whole
blood was diluted 1:1 with 500 μl normal saline in a plastic sample
cuvette and prewarmed for 5 minutes at 37 °C with a stirring speed
of 900 rpm. An electrode containing two ﬁne palladium wires was
inserted, allowing the platelets in the whole blood to adhere to the
wires, forming a uniform monolayer. A small voltage difference was
applied across the wires, and the electrical impedance was measured.
In the absence of an aggregatory agonist, the impedance between the
two wires became constant after 2 minutes, producing a stable base-
line which was calibrated using the chart recorder controls. When an
agonist is added to the cuvette, platelets and other constituents in the
blood become activated and start to aggregate, coating the palladium
wires on the electrode, causing a corresponding increase in electrical
impedance. This change in impedance is directly proportional to the
extent of aggregation and was measured 5 minutes after addition of
each agonist. 3 μg/ml collagen and 5 μM adenosine diphosphate
(ADP) (Labmedics Limited, Manchester, UK) were chosen as platelet
agonists, corresponding to their EC50 under control conditions. Indi-
vidual aggregation values for each experiment were calculated as a
percentage of control conditions. In experiments to investigate the ef-
fect of ROS, blood was incubated with X/XO for 1 minute prior to add-
ing either agonist. In additional control experiments, XO alone was
incubated prior to the agonist.Endothelial cell-platelet interaction
ECs were scraped from the pulmonary artery of fresh ex-vivo pig
hearts from a local abattoir. ECs were then cultured in large vessel EC
growth medium package (TCS Cellworks, Buckinghamshire, UK) and
grown to conﬂuence in cell culture ﬂasks. ECs were collected from the
ﬂasks using TrypLE Express (Invitrogen Corporation, Paisley UK) and
spundown in a centrifuge at 10,000 rpm for 5 minutes. The supernatant
was extracted and the ECs resuspended in 1 ml blank EC medium. The
number of ECs in 1 ml suspension was determined using a haemocyt-
ometer. 1×105 ECs were added to the sample cuvette using an appro-
priate volume of cell suspension and made up to 500 μl with normal
saline, to which 500 μl whole blood was added. In control experiments,
an equivalent volume of blank cell mediumwas added to the cuvette in
place of the cell suspension. WBA was tested as previously described
and the effect of ECs was determined in the absence and presence of
X/XO, and following 5 minutes pre-treatment of ECs with Nω-nitro-L-
arginine methyl ester (L-NAME) (Sigma-Aldrich, Dorset, UK), an inhib-
itor of •NO synthase.
Platelet nitrotyrosine expression
In order to establish the susceptibility of platelets to oxidative stress,
washed platelets were prepared according to the method of Cardoso et
al. [13]. Baseline nitrotyrosine (NT) expression and the effect of oxida-
tive stress was studied by incubating platelets for 10 minutes at room
temperature with 200 μM peroxynitrite (ONOO-), 100 mU/ml XO
alone or a combination of 100 μM xanthine and 100 mU/ml XO. Sam-
ples for western blotting were prepared by sedimenting the platelets,
homogenising the pellet in lysis buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.25% (w/v) Na-deoxycholate,
1% (v/v) TX-100, 1 x protease inhibitor cocktail) (Merck) and determin-
ing protein concentration using Coomassie Plus Protein Assay Reagent
(Perbio, Rockford, IL, USA). Samples were heated at 70 °C for 20 mi-
nutes prior to gel loading. All sampleswere run at the same time to con-
trol for inter-gel variation. SDS-PAGEwas performed using the NuPAGE
system (Invitrogen) with 4–12% tris–acetate gels followed by blotting
onto a nitrocellulose membrane (Invitrogen) by the Bradford method.
NT was detected using rabbit anti-nitrotyrosine primary antibody (di-
luted 1:5000, Upstate, Ca, USA) and goat anti-rabbit horseradish perox-
idase conjugate as secondary (Transduction Laboratories). Following
antibody incubation, membranes were treated with ECL reagent
(Pierce) and exposed onto ﬁlm. Detected bands were analysed densito-
metrically and corrected for background. GAPDH antibody (diluted
1:40000) was used to ensure equal protein loading in all wells.
Statistical analysis
All data are expressed as mean±SEM unless otherwise stated.
Groups were compared using repeated measures analysis of variance
and post-hoc Dunnett's test. Statistical signiﬁcance was conﬁrmed at
pb0.05. Statistical analysis was performed using the SPSS statistical
software package 14.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of study participants
33 patients with CHD were recruited and their baseline character-
istics are shown in Table 1. There was a high prevalence of cardiovas-
cular risk factors and regular medications prescribed. All CHD patients
were taking oral aspirin but no other antithrombotic medication. In
total, 16 healthy donors were recruited (mean [SD] age, 41.6 [17.2]
years; 62.5% male) and none had a history of cardiovascular disease
or were taking any antithrombotic medication at the time of the
study.
Table 1
Baseline characteristics of CHD patients.
(n=33)
Patients’ characteristics
Age, mean (SD), years 63.4 (8.9)
Male, n (%) 26 (78.8)
Current smoker, n (%) 9 (27.3)
Hypertension, n (%) 18 (54.5)
Hypercholesterolaemia, n (%) 23 (69.7)
Diabetes mellitus, n (%) 11 (33.3)
Family history of premature CHD, n (%) 13 (39.4)
Previous myocardial infarction, n (%) 13 (39.4)
Previous stroke, n (%) 2 (6.1)
Previous PCI or CABG, n (%) 15 (45.5)
Impaired LV function, n (%) 10 (30.3)
Heart failure, n (%) 3 (9.1)
Drug treatment
Aspirin, n (%) 33 (100.0)
Clopidogrel, n (%) 0 (0.0)
Statin, n (%) 31 (94.0)
ACE inhibitor or ARB, n (%) 25 (75.8)
Beta-blocker, n (%) 25 (75.8)
Calcium channel blocker, n (%) 12 (36.4)
Diuretic, n (%) 8 (24.2)
Nitrate, n (%) 18 (54.5)
Nicorandil, n (%) 12 (36.4)
Fig. 1. A, The effect of xanthine and XO on lucigenin chemiluminescence. XO caused a
concentration-dependent increase in chemiluminescence due to formation of O2-•. The
amount of luigenin-enhanced chemiluminescence was very strongly correlated with
XO concentration, using constant 100 μM xanthine (R=0.94, p=0.006). B, The effect
of SOD on chemiluminescence induced by X/XO. Chemiluminescence due to 100 μM
xanthine+10 mU/ml XO was completely abolished by 50 U/ml SOD, * pb0.001 vs.
control. CL=chemiluminescence; RLU/s=relative light units per second.
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There was a highly signiﬁcant positive correlation (r=0.94,
p=0.006) between chemiluminescence and XO concentration in the
presence of a constant concentration of 100 μM xanthine (Fig. 1A).
50 U/ml superoxide dismutase (SOD) completely abolished chemilumi-
nescence in the presence of 100 μM xanthine and 10 mU/ml XO
(pb0.001), indicating that O2-• was the principal active molecule gener-
ated under the conditions of these experiments (Fig. 1B).
Effects of ROS on WBA
There was no signiﬁcant difference in baseline aggregation to col-
lagen (15.4±0.8 Ω [n=23] vs. 15.9±1.5 Ω [n=12]) or ADP (9.3±
0.9 Ω [n=23] vs. 7.8±1.5 Ω [n=10]) between CHD patients and
healthy donors, respectively (both p=NS). The effect of oxidative
stress on WBA in 14 CHD patients was determined using the X/XO re-
action. The concentration of xanthine was kept constant at 100 μM,
while the concentration of XO was tested at 10, 50 and 100 mU/ml
to engender incremental levels of oxidative stress, previously con-
ﬁrmed using chemiluminescence. ROS produced by X/XO caused a
concentration-dependent inhibition of WBA in blood from CHD pa-
tients, for both collagen and ADP (Figs. 2A and B, respectively).
100 μM xanthine and 100 mU/ml XO inhibited WBA in response to
collagen by 28.9% (95% CI 15.9% - 41.8%, pb0.001) and in response
to ADP by 36.0% (95% CI 9.6% - 62.4%, p=0.005). Blood from healthy
donors also demonstrated concentration-dependent inhibition of
WBA in response to X/XO although this failed to reach statistical sig-
niﬁcance (n=4; Fig. 2 C), while addition of XO alone did not affect
WBA to either agonist (data not shown).
Endothelial cell-platelet interaction studies
The effects of cultured ECs onWBA in 9 CHD patients are shown in
Fig. 3A and B. The addition of 1 x 105 ECs caused a signiﬁcant decrease
in WBA in response to collagen by 31.2% (95% CI 12.2% - 50.2%,
pb0.01) and ADP by 31.6% (95% CI 2.5- 60.7%, pb0.05). The inhibitory
effect of ECs on WBA remained signiﬁcant after pre-treatment of ECs
with 100 μM xanthine and 10 mU/ml XO in response to collagen
(29.1% [95% CI 10.1% - 48.1%, pb0.01]) and ADP (32.6% [95% CI 3.4-
61.7%, pb0.05]). However, pre-treatment with 100 μM L-NAMEattenuated the inhibitory effect of ECs, which was no longer statisti-
cally signiﬁcant in response to collagen (21.6% [95% CI −7.2% -
50.5%, p=NS]) or ADP (9.2% [95% CI −44.7% - 63.1%, p=NS]).
Platelet nitrotyrosine expression
Baseline expression of NT in platelets from CHD patients and
healthy donors was similar (densitometric expression of all detected
bands was 10.93±3.0 in CHD patients [n=3] vs. 13.5±1.7 in healthy
donors [n=2], p=NS). In washed platelets from 7 CHD patients,
ONOO- caused an increase in platelet NT expression, whereas XO
and X/XO had a smaller effect on NT expression compared to baseline
(Fig. 4B). In healthy donors, none of the three treatments resulted in a
signiﬁcant increase in NT expression (Fig. 4B); however caution
should be exercised as only two samples were studied.
Discussion
Recently, evidence has accumulated that ROS are heavily involved
in the regulation of platelet function, although their precise role is
complex [2]. Therefore, clarifying the actions of ROS on WBA in
patients with CHD is important to extend our knowledge of the path-
ogenesis of acute atherothrombotic events [14].
Effect of ROS on platelet aggregation
The principal aim of the current study was to examine, for the ﬁrst
time, the effects of ROS on WBA in patients with clinically proven
Fig. 2. The effect of ROS on WBA in response to platelet agonists. Xanthine (μM)+XO
(mU/ml) caused a concentration-dependent inhibition of WBA in response to 3 μg/ml
collagen (A), 5 μM ADP (B) in blood from CHD patients and also in healthy donors
[black bars=collagen; white bars=ADP] (C), * pb0.05 vs. control.
Fig. 3. The effect of ECs alone and after pretreatment with X/XO or L-NAME on WBA in
blood from CHD patients. Cultured ECs inhibited WBA in response to 3 μg/ml collagen
(A) and 5 μM ADP (B). Inhibition was not affected by 100 μM xanthine and 10 mU/ml
XO but was no longer signiﬁcant after pre-treatment of ECs with 100 μM L-NAME,
* pb0.05 vs. control.
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caused a concentration-dependent inhibition of WBA in blood derived
from patients with CHD. This was clearly demonstrated in response to
the biologically relevant agonists, collagen and ADP. While we con-
ﬁrmed using chemiluminescence that O2-• was generated by X/XO, we
propose that secondary molecules may have exerted a major inﬂuence.
In addition to producing O2-•, the X/XO reaction also leads to down-
stream production of H2O2 [15], which modulates platelet function
[2]. Additionally, although resting platelets do not produce •NO, this is
formed following stimulation with platelet agonists [16] and can react
with O2-• to produce ONOO- [17]. ONOO-, unlike O2-•, is cell permeable
and would readily cross the platelet membrane. This highly reactive
molecule is known to be a potent oxidant and additional contributor
to platelet aggregation [18]. O2-• generated within platelets should also
be considered. It is reported that O2-• generation in response to collagen
occurs with a delay of 3–5 minutes and since wemeasured aggregationafter 5 minutes exposure, O2-• generated by the platelet may also have
contributed to the effects we observed. It is very difﬁcult to estimate
how the magnitude of platelet-derived O2-• compares to that generated
by X/XO in our experiments although it has been reported that O2-• for-
mation by platelets is similar to that by ECs [2]. We anticipate that
platelet-derived O2-• is likely to be quickly dismutated to form antiaggre-
gatory molecules such as H2O2 or lead to generation of ONOO-, both of
which are important mediators of aggregation and platelet function.
The hitherto reported effects of ROS on platelet function are vari-
able and depend on a variety of factors, particularly the type and con-
centration of ROS and the milieu in which they act. Using washed
platelets in buffer, exposure to X/XO led to irreversible aggregation
to subthreshold levels of ADP, although there was no effect on
collagen-induced platelet aggregation [19]. In another study, collagen
induced O2-• release from platelets, which stimulated ADP-dependent
platelet recruitment to preformed thrombus, but did not in itself
cause platelet aggregation [19]. Others have shown that addition of
X/XO to washed platelets led to release of the surrogate marker sero-
tonin, thought to occur as a result of platelet aggregation [20]. This ef-
fect was blocked by SOD suggesting that O2-• was the relevant
molecule involved. The O2-• generator pyrogallol increased thrombin-
induced platelet aggregation, an effect which was also blocked by
SOD [21], and increased arachidonic acid-induced platelet aggrega-
tion, an effect which was inhibited by dipyridamole [22]. Put togeth-
er, these data suggest the more likely effect of O2-• on platelet
aggregation is stimulatory, albeit mild in some cases. With regard to
potential mechanisms, Sill et al. demonstrated that intra-platelet in-
creases in oxidant status capable of activating platelet glycoprotein
IIb/IIIa receptors were iron-dependent, and neither O2-• (generated
by X/XO) nor H2O2 delivered externally to platelets produced this ef-
fect [23].
AB
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Fig. 4. The expression of nitrotyrosine in washed platelets. A, Representative blot
showing baseline NT expression (lane 1), effect of ONOO- (lane 2), XO alone (lane 3)
and X/XO (lane 4). GAPDH was used to ensure equal protein loading in each lane.
B, Bar chart showing effect of the three treatments on NT expression in CHD patients
and healthy donors (columns left to right represent baseline, ONOO-, XO, X/XO).
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led to different results. In healthy volunteers, X/XO caused potent in-
hibition of platelet aggregation in response to ADP, collagen and U-
46619 (a thromboxane mimetic) [24]. These ﬁndings were attributed
to an overproduction of H2O2, stimulation of guanylate cyclase and an
increase in cGMP. This inhibitory effect was blocked by catalase, but
not by SOD, suggesting that H2O2 was a crucial inhibitory ROS. The in-
hibitory effect of H2O2 on ADP-induced aggregation has also been
conﬁrmed in other studies [25,26]. There are reports that lower con-
centrations of H2O2 may enhance subthreshold collagen and arachi-
donic acid-induced aggregation, but not ADP-induced aggregation
[27,28]. The inﬂuence of ONOO- on isolated platelets has been varied,
causing both pro-aggregatory [29] and anti-aggregatory effects
[30,31], but studies in PRP consistently show that ONOO- inhibits col-
lagen, ADP, and thrombin-induced aggregation [29,32]. Subsequent
reports suggested that the •NO-dependent inhibitory effects of
ONOO- occurred at lower concentrations than the pro-aggregatory ef-
fects [33].
Taking all of these data into consideration, the actions of ROS on
platelet function are diverse, depend on the molecule involved, and
are concentration-dependent. Furthermore, assessment of platelet
function must take into account the environment in which aggrega-
tion is stimulated. Although washed platelets can provide informa-
tion regarding the speciﬁc actions of substances on platelets, more
physiological effects can be replicated in plasma or whole blood,
where other blood constituents and endogenous antioxidants are
represented that may antagonise the stimulation of platelets induced
by some ROS [34]. Our results indicate that ROS (generated by X/XO)
cause a concentration-dependent inhibition of platelet aggregation in
whole blood derived from patients with CHD. We propose that thiswas caused by the generation of secondary inhibitory ROS such as
H2O2 and ONOO-, possibly related to endogenous substances present
in whole blood. However, the exact mechanism of this effect should
be clariﬁed in future studies.
Effect of ROS on the endothelial cell-platelet interaction
For the ﬁrst time, we have demonstrated that healthy ECs main-
tain the ability to inhibit platelet aggregation in whole blood derived
from patients with CHD. A study by Kader et al. [35] found that trans-
fecting cultured ECs with eNOS reduced human platelet aggregation
in co-incubation experiments; suggesting that •NO production is like-
ly to mediate the anti-aggregatory effect. In addition, a previous study
by our group found that incubating whole blood with a ring of
endothelium-containing blood vessel could reduce platelet aggrega-
tion when the endotheliumwas stimulated pharmacologically to pro-
duce •NO [36]. As well as •NO, ECs may inhibit thrombosis through the
actions of prostacyclin [37] and the activity of an endothelial ecto-
ADPase present on the surface of ECs, identiﬁed as CD39 [38,39]. It
was reported that depolarization of ECs led to O2-• production, which
inactivated the ecto-ADPase, thereby decreasing the inhibitory prop-
erties of ECs on ADP-induced aggregation [40]. We have shown that
the addition of exogenous ROS using X/XO failed to inﬂuence the in-
hibitory properties of healthy ECs. We propose that this resulted
from an equilibrium of negative and positive effects, such as inactiva-
tion of EC-derived antiplatelet mechanisms (NO, ecto-ADPase) coun-
terbalanced by the production of secondary ROS which oppose
aggregation, as described. We have shown that the inhibitory effect
of healthy ECs is decreased by the pretreatment of ECs with
L-NAME. This supports the notion that isolated removal of EC-
derived •NO from the blood decreases its anti-aggregatory capacity,
which implies an increased risk of thrombosis where endothelial dys-
function occurs.
Platelet nitrotyrosine expression
ONOO- is cell permeable [41] and would readily cross the platelet
membrane when formed. Using immunoblotting, we measured total
NT expression in washed platelets. CHD patients did not express
higher levels of NT in platelets. Very few other studies have measured
this but in a canine model of acute coronary syndromes, platelet NT
was increased [42] and this could be normalised with tetrahydrobiop-
terin; suggesting that platelet •NO formation is important in regulat-
ing NT expression under baseline conditions. Following treatment
with ONOO-, NT expression was raised in CHD patients, but not in
healthy donors. Recent data has demonstrated that some supple-
ments such as L-carnitine can protect platelets against the nitrating
effects of ONOO- [43] and it is possible that platelet levels of endoge-
nous antioxidants were higher in healthy donors. Similarly, the O2-•
generating X/XO system or XO alone, which would likely generate
O2-• anions, also caused a small increase in platelet NT expression in
CHD patients, likely through an interaction with platelet-derived
•NO. Healthy donors showed no such increase, perhaps indicating
that •NO generation was lower and that platelets were in a non-
activated state compared to CHD. Such pre-activation has been
noted previously in patients with CHD [44].
Limitations
Direct comparison of results between CHD patients and healthy
controls in this study should take into consideration that groups
were not age or sex matched, in order to facilitate recruitment. All
CHD patients were taking regular oral antiplatelet medication (soley
aspirin, to provide consistency within the CHD group) which would
be expected to decrease WBA relative to healthy donors, none of
whom were receiving antithrombotic therapy. The main focus of
215J. Watt et al. / Thrombosis Research 130 (2012) 210–215this study was to investigate the effects of ROS on platelets derived
from patients with CHD.
Conclusion
ROS generated by X/XO produced a concentration-dependent inhib-
itory effect onWBA in blood obtained frompatientswith CHD. This con-
curs with previous studies in healthy individuals using X/XO as a source
of ROS and is likely to be a consequence of the formation of highly reac-
tive molecules such as H2O2 and ONOO- which have inhibitory effects
that appear to predominate. We have also shown that exogenous deliv-
ery of reactive molecules, especially ONOO-, is capable of causing dam-
aging effects to proteins within platelets. Healthy ECs maintain the
ability to carry out their physiological role to inhibit platelet aggregation
in blood derived from atherosclerotic human populations, even after
short term exposure to ROS, suggesting that strategies to preserve en-
dothelial function and •NO bioavailability are likely to be beneﬁcial.
However, prolonged damage to the endothelium may diminish the ca-
pacity of ECs to generate •NO, which would mitigate protection against
thrombosis and so may lead to a worse clinical outcome.
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